

Jua Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8973572/publications.pdf>

Version: 2024-02-01

20
papers

859
citations

623734

14
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

1047
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts. <i>Kidney International Reports</i> , 2022, 7, 720-731.	0.8	23
2	Viral-specific cytotoxic T cell responses in HLA-sensitized kidney transplant patients maintained on everolimus and low-dose tacrolimus. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	1
3	Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 1133-1144.	4.7	18
4	Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients. <i>Clinical Transplantation</i> , 2022, 36, .	1.6	7
5	Imlifidase Inhibits HLA Antibody-mediated NK Cell Activation and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) In Vitro. <i>Transplantation</i> , 2020, 104, 1574-1579.	1.0	26
6	Interleukin-6: An Important Mediator of Allograft Injury. <i>Transplantation</i> , 2020, 104, 2497-2506.	1.0	41
7	The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 42-56.	4.7	27
8	Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation. <i>Transplantation</i> , 2019, 103, 2666-2674.	1.0	19
9	Novel Therapeutic Approaches to Allosensitization and Antibody-mediated Rejection. <i>Transplantation</i> , 2019, 103, 262-272.	1.0	28
10	A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients. <i>American Journal of Transplantation</i> , 2018, 18, 2955-2964.	4.7	70
11	Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. <i>Kidney International</i> , 2017, 91, 729-737.	5.2	77
12	Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients. <i>Pediatric Transplantation</i> , 2017, 21, e13042.	1.0	4
13	IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 442-453.	27.0	257
14	Desensitization: Overcoming the Immunologic Barriers to Transplantation. <i>Journal of Immunology Research</i> , 2017, 2017, 1-11.	2.2	67
15	Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. <i>Journal of Immunology Research</i> , 2017, 2017, 1-24.	2.2	28
16	Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. <i>Transplant International</i> , 2016, 29, 1276-1285.	1.6	38
17	Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. <i>Transplantation</i> , 2015, 99, 1423-1430.	1.0	61
18	Kidney transplantation in highly sensitized patients. <i>British Medical Bulletin</i> , 2015, 114, 113-125.	6.9	63

#	ARTICLE	IF	CITATIONS
19	Strategies to Improve Novel Drug Development in Kidney Transplantation Through the Clinical Trials Process. <i>Clinical Transplants</i> , 2015, 31, 163-172.	0.2	0
20	Immunologic and Infectious Complications in Highly Sensitized Patients Post-Kidney Transplantation. <i>Clinical Transplants</i> , 2015, 31, 265-273.	0.2	1